Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Related to this article
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are transforming thoracic surgical nursing care.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
IMS 2026: Beth Faiman Talks New Definition of Myeloma Cure and More
2
Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management
3
Surveillance, Patient Resources, and Financial Support
4
Community Case Forum Explores Advancements and Care Collaboration in CLL
5